Literature DB >> 23240670

Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.

Ananta Gurung1, Tawny Hung, Jason Morin, C Blake Gilks.   

Abstract

The histopathological classification of ovarian surface epithelial carcinomas (referred to hereafter as 'ovarian carcinoma') has shifted over the past 10 years to reflect more clearly our understanding of molecular events during carcinogenesis. Ovarian carcinoma is no longer viewed as a single entity but as multiple disease processes, with each having different molecular pathways altered during oncogenesis, resulting in differences in clinical and pathological features, such as biomarker expression, pattern of spread and response to chemotherapy. There are five subtypes of ovarian carcinoma that are sufficiently distinct and well-characterized that they should be considered to be different diseases, i.e. high-grade serous, clear cell, endometrioid, mucinous and low-grade serous, from most to least common, respectively. This review summarizes the molecular abnormalities of these five ovarian carcinoma subtypes, relating them to clinical and pathological features.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23240670     DOI: 10.1111/his.12033

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  32 in total

Review 1.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

2.  Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.

Authors:  Shaomei Cheng; Jingyan Guo; Qing Yang; Xiangshan Yang
Journal:  Med Oncol       Date:  2015-01-31       Impact factor: 3.064

Review 3.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 4.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

5.  Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.

Authors:  Yuji Takei; Suzuyo Takahashi; Shizuo Machida; Akiyo Taneichi; Takahiro Yoshiba; Yoshifumi Takahashi; Chikako Yoshida; Yasushi Saga; Shigeki Matsubara; Hiroyuki Fujiwara
Journal:  Int J Clin Oncol       Date:  2018-04-20       Impact factor: 3.402

6.  Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Authors:  Robertson Mackenzie; Aline Talhouk; Sima Eshragh; Sherman Lau; Daphne Cheung; Christine Chow; Nhu Le; Linda S Cook; Nafisa Wilkinson; Jacqueline McDermott; Naveena Singh; Friedrich Kommoss; Jacobus Pfisterer; David G Huntsman; Martin Köbel; Stefan Kommoss; C Blake Gilks; Michael S Anglesio
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

Review 7.  [Serous ovarian tumors].

Authors:  J Diebold
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

8.  A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas.

Authors:  Hiroaki Soyama; Morikazu Miyamoto; Masashi Takano; Hideki Iwahashi; Kento Kato; Takahiro Sakamoto; Mika Kuwahara; Hiroki Ishibashi; Hiroko Matuura; Tomoyuki Yoshikawa; Tadashi Aoyama; Hitoshi Tsuda; Kenichi Furuya
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

Review 9.  Risk-reducing salpingectomy: Let us be opportunistic.

Authors:  Kara C Long Roche; Nadeem R Abu-Rustum; Mlica Nourmoussavi; Oliver Zivanovic
Journal:  Cancer       Date:  2017-03-23       Impact factor: 6.860

10.  HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.

Authors:  Wen-Yee Chay; Sung-Hock Chew; Whee-Sze Ong; Inny Busmanis; Xinyun Li; Sharyl Thung; Lynette Ngo; Sheow-Lei Lim; Yong-Kuei Lim; Yin-Nin Chia; Elisa Koh; Cindy Pang; Lay-Tin Soh; Jin Wang; Tew-Hong Ho; Sun-Kuie Tay; Soo-Kim Lim-Tan; Kiat-Hon Lim; John Whay-Kuang Chia; Liang-Kee Goh
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.